Cargando…

重型再生障碍性贫血患者SLAMF6表达状态的初步研究

OBJECTIVE: To explore the expression of SLAMF6 on CD8(+) T cells in patients with severe aplastic anemia (SAA) and its correlation with disease immune status. METHODS: By flow cytometry (FCM), SLAMF6 expression level in peripheral blood CD8(+) T cells was detected in 21 patients with SAA and 15 norm...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342346/
https://www.ncbi.nlm.nih.gov/pubmed/30486590
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.11.011
_version_ 1783555453503930368
collection PubMed
description OBJECTIVE: To explore the expression of SLAMF6 on CD8(+) T cells in patients with severe aplastic anemia (SAA) and its correlation with disease immune status. METHODS: By flow cytometry (FCM), SLAMF6 expression level in peripheral blood CD8(+) T cells was detected in 21 patients with SAA and 15 normal controls respectively from February 2017 to April 2018. The correlation between SLAMF6 expression level and hematopoietic functions, including HGB, PLT, the neutrophil granulocyte and reticulocyte absolute value in peripheral blood, hyperplasia degree (percentage of granulocytes, erythrocytes, lymphocytes and megakaryocytes in bone marrow) and perforin, granzyme B, IFN-γ expression level in CD8(+) T cells were evaluated. To further confirm the effect of SLAMF6 on CD8(+) T cells, anti-SLAMF6 Ab was used to block SLAMF6 pathway (IgG as control), and FCM was used to detect the perforin, granzyme B, and IFN-γ production of CD8(+) T cells. RESULTS: The expression of SLAMF6 on CD8(+) T cells in untreated SAA patients [(56.29±12.97)%] was significantly lower than that of normal controls [(80.96±7.36)%] (t=−7.672, P<0.001). The expression of SLAMF6 on CD8(+) T cells in SAA patients were positively correlated with the HGB, PLT, the neutrophil granulocyte and reticulocyte absolute value in peripheral blood, percentage of granulocytes, erythrocytes in bone marrow (all P<0.05), but they were negatively correlated with the percentage of lymphocytes in bone marrow, and the expression of perforin, granzyme B, and IFN-γ of CD8(+) T cells (all P<0.05). After blocking SLAMF6 pathway by anti-SLAMF6 Ab, the expression levels of perforin, granzyme B and IFN-γ in SAA patients were significantly higher than those in the untreated group, and the differences were statistically significant (all P<0.05). CONCLUSION: SLAMF6 is significantly down-regulated on CD8(+) T cells in SAA patients, which may act as a negative immunoregulatory molecule participating in the mechanism of SAA by affecting the functional molecules secretion on CD8(+) T cells.
format Online
Article
Text
id pubmed-7342346
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73423462020-07-16 重型再生障碍性贫血患者SLAMF6表达状态的初步研究 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To explore the expression of SLAMF6 on CD8(+) T cells in patients with severe aplastic anemia (SAA) and its correlation with disease immune status. METHODS: By flow cytometry (FCM), SLAMF6 expression level in peripheral blood CD8(+) T cells was detected in 21 patients with SAA and 15 normal controls respectively from February 2017 to April 2018. The correlation between SLAMF6 expression level and hematopoietic functions, including HGB, PLT, the neutrophil granulocyte and reticulocyte absolute value in peripheral blood, hyperplasia degree (percentage of granulocytes, erythrocytes, lymphocytes and megakaryocytes in bone marrow) and perforin, granzyme B, IFN-γ expression level in CD8(+) T cells were evaluated. To further confirm the effect of SLAMF6 on CD8(+) T cells, anti-SLAMF6 Ab was used to block SLAMF6 pathway (IgG as control), and FCM was used to detect the perforin, granzyme B, and IFN-γ production of CD8(+) T cells. RESULTS: The expression of SLAMF6 on CD8(+) T cells in untreated SAA patients [(56.29±12.97)%] was significantly lower than that of normal controls [(80.96±7.36)%] (t=−7.672, P<0.001). The expression of SLAMF6 on CD8(+) T cells in SAA patients were positively correlated with the HGB, PLT, the neutrophil granulocyte and reticulocyte absolute value in peripheral blood, percentage of granulocytes, erythrocytes in bone marrow (all P<0.05), but they were negatively correlated with the percentage of lymphocytes in bone marrow, and the expression of perforin, granzyme B, and IFN-γ of CD8(+) T cells (all P<0.05). After blocking SLAMF6 pathway by anti-SLAMF6 Ab, the expression levels of perforin, granzyme B and IFN-γ in SAA patients were significantly higher than those in the untreated group, and the differences were statistically significant (all P<0.05). CONCLUSION: SLAMF6 is significantly down-regulated on CD8(+) T cells in SAA patients, which may act as a negative immunoregulatory molecule participating in the mechanism of SAA by affecting the functional molecules secretion on CD8(+) T cells. Editorial office of Chinese Journal of Hematology 2018-11 /pmc/articles/PMC7342346/ /pubmed/30486590 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.11.011 Text en 2018年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
重型再生障碍性贫血患者SLAMF6表达状态的初步研究
title 重型再生障碍性贫血患者SLAMF6表达状态的初步研究
title_full 重型再生障碍性贫血患者SLAMF6表达状态的初步研究
title_fullStr 重型再生障碍性贫血患者SLAMF6表达状态的初步研究
title_full_unstemmed 重型再生障碍性贫血患者SLAMF6表达状态的初步研究
title_short 重型再生障碍性贫血患者SLAMF6表达状态的初步研究
title_sort 重型再生障碍性贫血患者slamf6表达状态的初步研究
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342346/
https://www.ncbi.nlm.nih.gov/pubmed/30486590
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.11.011
work_keys_str_mv AT zhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěslamf6biǎodázhuàngtàidechūbùyánjiū
AT zhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěslamf6biǎodázhuàngtàidechūbùyánjiū
AT zhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěslamf6biǎodázhuàngtàidechūbùyánjiū
AT zhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěslamf6biǎodázhuàngtàidechūbùyánjiū
AT zhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěslamf6biǎodázhuàngtàidechūbùyánjiū
AT zhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěslamf6biǎodázhuàngtàidechūbùyánjiū